News / Taiwan / economic_daily

QIC: Taiwan Biotech Sector Poised for Growth as Capital Shifts from AI-Driven Tech Stocks

Health Technology · Biotechnology · economic_daily · 2026-08-24

6446, 6712, 6841, 6891, 7850

QIC CEO Felix Li suggests that as AI and semiconductor valuations peak, capital rotation into Taiwan's resilient biotech sector could trigger exponential market cap growth.

What Happened

Capital Rotation Outlook: As AI and semiconductor stocks reach historical valuation highs, market participants are increasingly looking for defensive yet high-growth alternatives. QIC suggests that Taiwan's biotech sector is emerging as a primary destination for capital seeking a safe haven with significant upside potential.

Market Cap Expansion: Currently, biotech accounts for only 1.4% of Taiwan's total market capitalization, compared to 75% for the tech and semiconductor supply chain. Analysts estimate that a shift of just 1.5 percentage points from tech into biotech could trigger an exponential surge in the sector's total valuation.

Sector Depth and Resilience: With over 250 companies spanning innovative drugs, CDMO services, and high-end medical devices, Taiwan's biotech ecosystem is uniquely positioned to absorb large-scale capital inflows. This comprehensive value chain provides the necessary capacity to support a major rotation away from overheated tech stocks.

Superior Performance: Historical data indicates that the Taiwan Biotech Index has consistently outperformed both the NASDAQ Biotechnology Index (NBI) and the Hang Seng Biotech Index since 2020. Supported by inelastic demand and favorable policies, the sector is being positioned as a key long-term growth engine for the next decade.

Read original